(3-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-2-yl)methanol | 780803-19-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (3-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-2-yl)methanol
• 英文别名: 3-({[tert-butyl(dimethyl)silyl]oxy}methyl)pyridine-2-ylmethanol；[3-[[tert-butyl(dimethyl)silyl]oxymethyl]pyridin-2-yl]methanol
• CAS: 780803-19-2
• 化学式: C₁₃H₂₃NO₂Si
• 分子量: 253.417
• InChiKey: GVEXLHVCXNKVQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-2-yl)methanol 在 manganese(IV) oxide 作用下， 以 二氯甲烷 为溶剂， 生成 3-({[tert-butyl(dimethyl)silyl]oxy}methyl)pyridine-2-carbaldehyde
  参考文献：
  名称：

  Synthesis and Biological Activities of Topoisomerase I Inhibitors, 6-Arylmethylamino Analogues of Edotecarin

  摘要：

  The replacement of 1,3-dihydroxy-2-propylamino moiety at the N6-position of edotecarin (1) by arylmethylamino groups yielded a number of more potent topoisomerase I inhibitors with better cytotoxic (CTX) activities in vitro than edotecarin. Among them, the three most potent pyridylmethyl analogues, compounds 22g, 22m, and 23c, showed better antitumor activities against MKN-45 human stomach cancer or MX-1 human breast cancer xenografted mice than those of edotecarin. Furthermore, compounds 22m and 23c exhibited complete response against MX-1 cells implanted in mice.

  DOI：

  10.1021/jm801641t
• 作为产物：
  描述：

  2,3-吡啶二羧酸酐 在 咪唑 、 lithium aluminium tetrahydride 、 二氯化硫 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.25h， 生成 (3-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-2-yl)methanol
  参考文献：
  名称：

  Compounds and Their Use in Treating Cancer

  摘要：

  本说明书一般涉及公式(I)的化合物： 以及药学上可接受的盐和前药，其中R1、R4、R5、R6、R7、Linker、X、Y、A、G、D和E具有此处定义的任何含义。本说明书还涉及将此类化合物以及药学上可接受的盐和前药用于治疗人体或动物体的方法，例如用于预防或治疗癌症。本说明书还涉及制备此类化合物涉及的工艺和中间化合物，以及含有它们的药物组合物。

  公开号：

  US20190194190A1

文献信息

• Compounds and Their Use in Treating Cancer
  申请人：AstraZeneca AB

  公开号：US20190194190A1

  公开（公告）日：2019-06-27

  The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R 1 , R 4 , R 5 , R 6 , R 7 , Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

  本说明书一般涉及公式(I)的化合物： 以及药学上可接受的盐和前药，其中R1、R4、R5、R6、R7、Linker、X、Y、A、G、D和E具有此处定义的任何含义。本说明书还涉及将此类化合物以及药学上可接受的盐和前药用于治疗人体或动物体的方法，例如用于预防或治疗癌症。本说明书还涉及制备此类化合物涉及的工艺和中间化合物，以及含有它们的药物组合物。
• Synthesis and Biological Activities of Topoisomerase I Inhibitors, 6-Arylmethylamino Analogues of Edotecarin
  作者：Satoshi Sunami、Teruyuki Nishimura、Ikuko Nishimura、Satoru Ito、Hiroharu Arakawa、Mitsuru Ohkubo

  DOI：10.1021/jm801641t

  日期：2009.5.28

  The replacement of 1,3-dihydroxy-2-propylamino moiety at the N6-position of edotecarin (1) by arylmethylamino groups yielded a number of more potent topoisomerase I inhibitors with better cytotoxic (CTX) activities in vitro than edotecarin. Among them, the three most potent pyridylmethyl analogues, compounds 22g, 22m, and 23c, showed better antitumor activities against MKN-45 human stomach cancer or MX-1 human breast cancer xenografted mice than those of edotecarin. Furthermore, compounds 22m and 23c exhibited complete response against MX-1 cells implanted in mice.